Study on Yangxue Nao Granules Reducing the Risk of Stroke
A Real World Study of Yangxuenao Granules Reducing Bleeding Risk in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis
1 other identifier
observational
150
1 country
1
Brief Summary
Objective: To explore the effectiveness of raising serum nao granules in reducing the risk of bleeding in patients with acute ischemic stroke treated with intravenous thrombolysis in the real world
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2020
CompletedFirst Submitted
Initial submission to the registry
June 27, 2021
CompletedFirst Posted
Study publicly available on registry
July 2, 2021
CompletedJuly 6, 2021
June 1, 2021
1.3 years
June 27, 2021
July 2, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Microhemorrhage (CMB) of T2* sequence in MRI after thrombolysis
The number of CMB is an important imaging marker reflecting microvascular injury.
1 day
Study Arms (2)
The experimental group
The application of raising serum brain granules
The control group
No nourishing serum brain granules are used
Interventions
Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
No nourishing serum brain granules are used
Eligibility Criteria
A cohort of patients admitted to the Department of Emergency Neurology at Peking University Third Hospital on January 1, 2017 and admitted on September 30, 2019, who were diagnosed with acute ischemic stroke and underwent intravenous thrombolysis.
You may qualify if:
- A cohort of patients admitted to the Department of Emergency Neurology at Peking University Third Hospital on January 1, 2017 and admitted on September 30, 2019, who were diagnosed with acute ischemic stroke and underwent intravenous thrombolysis.
You may not qualify if:
- Patients who underwent intravenous thrombolysis but were confirmed to be apoplexy
- like by imaging and other clinical examinations; Incomplete craniocerebral MRI examination;
- Bridging endovascular therapy;
- The previous application of Yangxuenao granules or other drugs with similar effects;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking Yniversity Third Hospital
Beijing, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 27, 2021
First Posted
July 2, 2021
Study Start
June 1, 2019
Primary Completion
September 1, 2020
Study Completion
November 1, 2020
Last Updated
July 6, 2021
Record last verified: 2021-06
Data Sharing
- IPD Sharing
- Will not share